Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell Culture

Dieter Gruenert's Biography

Dieter Gruenert, Professor, University of California San Francisco

Dieter C. Gruenert, Ph.D.: Dieter C. Gruenert, Ph.D., is a Professor in the Departments of Otolaryngology-Head and Neck Surgery and Laboratory Medicine at UCSF as well as in the Department of Pediatrics at the University of Vermont. He received his Ph.D. in Biophysics from the University of California, Berkeley in 1982. His postdoctoral studies (1982-1984) were in the Department of Carcinogenesis at the Swiss Institute for Experimental Cancer Research. Prior to his present position, he was a Professor of Laboratory Medicine and the Co-Director of the Gene Therapy Core Center at UCSF (1992-1999), Professor of Medicine and Director, Division of Human Molecular Genetics at the University of Vermont (2000-2003), and a Senior Scientist and Head of the Stem Cell Research Program at the California Pacific Medical Center (2003-2010). His research emphasis is on human cell and molecular biology, nucleic acid delivery, and the development of gene, pharmacological, and cell-based therapies for the treatment of inherited diseases and cancer. His work has led to the development of novel diagnostic and oligo/polynucleotide-based therapeutic strategies to ameliorate disease pathology, as well as to numerous human epithelial cell systems now used in academic and industrial labs throughout the world. His work focuses on development of adult, embryonic, and induced pluripotent stem cells as well as development of novel approaches for generating immortalized cell systems to study the biochemical, molecular, and metabolic mechanisms underlying disease progression and to develop pharmacological, genetic, and/or regenerative therapies. He has > 140 publications and holds 5 patents. Dr. Gruenert is on the Editorial Boards of several scientific journals including Molecular Therapy, Molecular Therapy Nucleic Acids, Pharmaceutical Sciences, and Current Drug Discovery, and he is a Senior Editor of Nucleic Acids Therapeutics. He reviews grants for numerous public and private agencies both nationally and internationally including the NIH, the DOD, the VA, the Maryland and Connecticut Stem Cell Programs, the CF Foundation, the Medical Research Council, the German, Italian, and French CF Foundations, the Italian, German and French Ministry of Health/Science. He currently serves on the Ethics Committee (Chair, 2005-2008) and the Oligonucleotide-based Therapy Committee of the ASGCT and was awarded a European Respiratory Society Visiting Professorship at Necker Sick Children's Hospital in Paris (2009) and holds an ongoing Visiting Professorship at Tor Vergata University in Rome. He has consulted for such biotech and pharma firms as Bayer, Boehringer Mannheim, Boehringer Ingelheim, Promega, AMAXA, and Discovery BioMed.

Dieter Gruenert Image

Organ/Tissue-specific Human Cell Systems for Development of Novel Therapies

Tuesday, 22 January 2013 at 11:15

Add to Calendar ▼2013-01-22 11:15:002013-01-22 12:15:00Europe/LondonOrgan/Tissue-specific Human Cell Systems for Development of Novel Therapies

The prospect of using human cell systems to model disease pathology has significantly enhanced the ability to develop novel patient-specific therapies.  Both cell immortalization and stem cell technology have provided multiple opportunities to generate human cell systems that have features that are characteristic of specific organs/tissues and/or disease pathology.  Immortalized cells can be generated to have features that reflect the parental cell of origin, while somatic cell-derived induced pluripotent stem (iPS) cells from any individual can be directed to differentiate into tissue/organ-specific precursor cells (e.g., hematopoietic, parathyroid, salivary gland, airway, thyroid, breast, etc) that have the potential of regenerating/repairing tissues damaged by disease pathology and/or therapeutic intervention (e.g., surgery, radiation, or chemotherapy). These cells can be used to evaluate therapeutic interventions in multiple tissue types in a given patient and have the potential for developing and optimizing patient specific therapies.

Add to Calendar ▼2013-01-22 00:00:002013-01-23 00:00:00Europe/LondonCell